During Wednesday’s Current trade, Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), lost -0.22% to $31.93.
Sarepta Therapeutics Inc (SRPT) a developer of innovative RNA-targeted therapeutics, granted an equity award recently to Rachel Chan. The award was formerly approved by the Compensation Committee of Sarepta’s Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to Ms. Chan’s employment as a Chemistry Lab Aide at Sarepta in May 2015. The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4).
Ms. Chan received an option to purchase 600 shares of Sarepta’s common stock. The option has an exercise price of $25.62 per share, which is equal to the closing price of Sarepta’s common stock on May 29, 2015. One-fourth of the shares underlying Ms. Chan’s option will vest on the one year anniversary of her date of hire and thereafter 1/48th of the shares underlying Ms. Chan’s option will vest monthly, such that the shares underlying the option will be fully vested on the fourth anniversary of her date of hire, subject to her continued employment with Sarepta on each such vesting date.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH), inclined 7.09% to $9.54, during its current trading session.
Anthera Pharmaceuticals, Inc. (ANTH), declared that it has accomplished the formerly declared underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which comprises the exercise in full by the underwriters of their option to purchase 500,000 additional shares of common stock. The aggregate gross proceeds to the Company from the sale of shares in this offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, are about $28.8 million. Anthera intends to use the net proceeds from this offering for clinical research and development and general corporate purposes.
Citigroup Global Markets Inc. and Piper Jaffray & Co. acted as joint book-running managers for the offering. SunTrust Robinson Humphrey acted as co-manager.
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for patients with unmet medical needs. It is developing blisibimod, a Phase III product candidate that targets B-cell activating factor associated with various B-cell mediated autoimmune diseases, counting systemic lupus erythematosus, Immunoglobulin A nephropathy, lupus nephritis, and others. The company is also developing a Phase III product candidate Liprotamase, a non-porcine investigational pancreatic enzyme replacement therapy intended for the treatment of patients with exocrine pancreatic insufficiency. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
Honeywell International Inc. (NYSE:HON), during its Wednesday’s current trading session gained 0.29% to $104.38.
Honeywell (HON) Process Solutions (HPS) declared that its technology will assist improve operations for China’s long-distance Guangxi liquefied natural gas (LNG) high-pressure pipeline.
A key planned project of Sinopec Limited and Guangxi Zhuang Autonomous Region, the Guangxi LNG pipeline will play a critical role in optimizing China’s energy structure and meeting the demand for natural gas in Guangxi. The project will use HPS gas measurement and equipment and software to measure the flow and pressure in the pipeline.
Honeywell International Inc. operates as a diversified technology and manufacturing company worldwide. Its Aerospace segment provides aircraft engines, integrated avionics, systems and service solutions, and related products and services for aircraft manufacturers and operators, airlines, military services, and defense and space contractors; and spare parts, and repair and maintenance services for the aftermarket.
Finally, ASML Holding NV (ADR) (NASDAQ:ASML), gained 4.77%, to $108.10.
Cymer, an ASML company, an industry leader in developing lithography light sources used by chipmakers to pattern advanced semiconductor chips, declared a neon gas reduction program for the installed base of argon fluoride (ArF) and krypton fluoride (KrF) light sources. The program comprises new light source software to reduce neon consumption across the installed base of light sources, rapid qualification of new gas suppliers, and a light source upgrade to enable reclaim of used neon, allowing gas suppliers to reuse existing neon and further reduce the need for additional supplies. The neon gas reduction program has been put in place by Cymer to reduce dependence on neon, a key gas for operation of the light source, and to insulate our customers from fluctuations of neon supply.
The neon reduction program is presently underway with customers participating in OnPulse, Cymer`s industry leading support program for light source maintenance, receiving the light source improvements without additional cost as part of the ongoing benefits of OnPulse subscription coverage. This furthers Cymer commitment to reducing customer dependence on process gasses, having introduced a helium reduction kit earlier this year for all OnPulse customers.
ASML Holding N.V. engages in the development, production, marketing, sale, and servicing of advanced semiconductor equipment systems with a focus on lithography related systems worldwide. It provides PAS 5500 family products, which comprise wafer steppers, and step and scan systems with i-line, krypton fluoride, and argon fluoride light sources for processing wafers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
